New hope for tough pancreatic cancer: electric pulses plus immune-boosting drug

NCT ID NCT07306273

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people with locally advanced pancreatic cancer whose first chemotherapy (AG) has stopped working. The treatment combines a procedure called irreversible electroporation (IRE), which uses electric pulses to destroy cancer cells, with an investigational drug (Apalulizumab) that helps the immune system attack the tumor. The goal is to see if this combination can improve survival and offer a new second-line option. The study will enroll about 20 adults.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA LOCALLY ADVANCED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 2000010, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••